“The approval of FORZINITY, the first treatment option for Barth syndromeA rare, genetic disorder of lipid metabolism that primarily affects males. and the first approved mitochondria-targeted therapeutic, is a pivotal victory for the Barth syndrome community and offers hope for expedited regulatory attention to other ultra-rare diseases,” said Reenie McCarthy, Stealth’s Chief Executive Officer.
Click HERE to read the full press release from Stealth Biotherapeutics
